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Abstract
Background: Canine Distemper Virus (CDV) and Canine Parvovirus (CPV) lead to infections with high mortality
rates in dogs. These viruses affect unvaccinated dogs or dogs with incomplete vaccination protocols.
Vaccination plays an important role in reducing death rates, preventing clinical cases and controlling the
spread of virus However, the efficacy of vaccination might be affected by different factors including vaccine
scheduling and the neutralization of the vaccine targets by maternal antibodies. In face of these factors, the
main goals of this study are (i) to investigate the antibody responses of puppies undergoing different primary
vaccination protocols against CPV and CDV and (ii) to estimate the time until seroreversion in adult dogs
unvaccinated for at least 3 years.
Results: Antibody protection against CDV and CPV was evaluated in a total of 20 dogs: 5 puppies that
initiated immunization at 6 weeks after birth (group A), 8 animals that started vaccination between 8 and
12 weeks of age (group B), and 7 adult dogs that have not been vaccinated for at least 3 years (group C).
Blood samples were collected from each animal, with 3 to 4 weeks apart. Antibody responses were measured
using indirect ELISA. In the second immunization point, no significant differences were found between the
seroconversion of groups A and B for each viral infection (p = 0.81 and 0.20 for CDV and CPV, respectively). In
the third immunization, there was evidence for a shorter time to achieve a protective titer against CPV in
group B when compared to group A (p = 0.015). Similar evidence was not found for CDV (p-value = 0.41). In
Group C, the average time until seroveversion was estimated at 2.86 years and 7.63 years for CDV and CPV,
respectively.
Conclusion: Vaccine response to CDV and CPV is specific in each individual. Effective immune protection in
primary vaccination depends mainly on the initial titer of maternal antibodies acquired by the neonate. Other
factors such as environmental exposure, immunization schedules and immune system activity influence the
duration of immunity in adult dogs. The variability found reinforces the need to determine individual humoral
immunity levels in order to assess vaccine efficacy.
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Background
Canine parvovirus (CPV) and Canine Distemper Virus
(CDV) cause life-threatening infections with a major im-
pact on the canine population [1, 2]. These viruses are
distributed worldwide affecting both domestic and wild-
life mammals [2]. In dogs, CPV is an important enteric
pathogen because of the associated high morbidity and
mortality rates [3]. It can affect dogs of any age, but se-
vere infections are most likely to occur between 6 weeks
and 6months after birth [3]. Since CPV is a DNA virus
without an envelope, it is highly resistant to adverse en-
vironmental conditions and persistent on fomites and
cage floors for more than a year [4]. CPV inactivation
can be achieved by agents include sodium hypochlorite
and potassium peroxymonosulfate [4, 5].
Infections by CDV show a range of symptoms in dogs
including fever, respiratory, enteric and neurological signs
[6, 7]. In these infections, young dogs with age between 3
and 6 months are more like to show clinical symptoms
than older ones [6]. In contrast to CPV, CDV can be easily
inactivated using UV radiation, heat, desiccation, oxidizing
agents, detergents and lipid solvents [6].
Vaccination has proven successful to prevent future
CPV and CDV infections [8–10]. Current recommenda-
tions suggest that puppies should have the first (or pri-
mary) vaccination scheduled between the first 6 and
8 weeks of age, followed by several boosts administered
in intervals of 3 or 4 weeks until 16 weeks of age. At this
point, maternal antibodies are expected to have declined
so their chance of interfering with the vaccine antigen is
low [11–13]. The number of vaccine boosts required
during this phase might vary with age at which the vac-
cination protocol began [10]. For example, if the first
vaccination has been administered 16 weeks after birth,
a single dose may be sufficient to achieve protection
[10]. In adult dogs, vaccination should be carried out
every 3 years [10].
Vaccination stimulates both humoral response via
antibody production and cellular responses via B and T
lymphocytes [14]. The duration of immunity is mainly
dependent on the degree of immunological memory de-
veloped [12, 14, 15]. However, it is unclear whether a
vaccinated dog is fully protected throughout its life or
whether revaccination is always necessary [16]. To clarify
these issues, it is important to quantify the rate by which
vaccinated animals become sero-naive again, the
so-called seroreversion rate (SRR) [14]. Under the as-
sumption that serum antibody titer is correlated with
protective immunity, antibody quantification may be
seen as a way to assess the immune protection in vacci-
nated and unvaccinated animal [17, 18].
The pharmaceutical industry has been developing tests
for antibody quantification associated with CPV and
CDV exposure in canines [19]. These tests should be
performed within 3 to 4 weeks after vaccine administra-
tion to assess the necessity of further vaccination steps
[10]. This evaluation is essential to reduce the number
of necessary immunization shots and to detect possible
vaccine failures, thus, decreasing the chance of having a
large pool of susceptible animals in the population [20].
From an animal health perspective, the improvement
of current vaccine protocols is important to reduce the
high incidence of CPV and CDV in the canine popula-
tion. In this scenario, this work has the objective of in-
vestigating the seroconversion to CPV and CDV in two
groups of puppies undergoing two different primary vac-
cination protocols. It also aims to evaluate the sero-
logical status associated with CPV and CDV in a group
of adult dogs unvaccinated for at least 3 years and to es-
timate the respective seroreversion rate.
Results
All dogs included in this study were dewormed and evalu-
ated by a veterinarian from the Veterinary Teaching Hos-
pital (VTH, Faculty of Veterinary Medicine, University of
Lisbon) before each vaccination. Only dogs deemed
healthy were allowed to start the vaccination protocol.
Dogs deemed unhealthy at the vaccination appointment,
dogs that failed the immunization schedule, dogs that
started vaccination after 12 weeks of age and dogs whose
age was unknown, were excluded from the study.
The above exclusion criteria discarded 64 out of 84
available dogs of different races, sex and ages. The study
was then carried out in 20 dogs with following distribu-
tion across three vaccination groups: A (n = 5), B (n = 8)
and C (n = 7) (Tables 1 and 2).
Group A consisted of five dogs from the same litter
that started vaccination at 6 weeks and were followed
for humoral protection evaluation until 12 weeks of
age (Table 1). Group B encompassed eight older pup-
pies from different origins, which began vaccination
at 8 to 12 weeks. This group enabled the analysis of
antibody protection beyond the 16 weeks of age. In
these groups, there was no data on immune status of
the respective parents. It was also unknown the
amount of colostrum ingested by each puppy. Group
C referred to seven adult animals unvaccinated for at
least 3 years (Table 2). The age of these animals var-
ied from 3.7 to 18 years old with an average of
9.7 years. Six out of seven dogs were vaccinated be-
fore this study. The average time since vaccination
was 7.2 years with a range from 3 to 12 years.
In order to assess humoral response/seroconversion,
blood samples were collected before and after vaccin-
ation in groups A and B. There was then a total of 39
blood samples. Antibody quantification was performed
using indirect ELISA [10]. In Group C, a single blood
sample per dog was collected for serological screening.
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In group A, all dogs were unprotected against CDV
before vaccination using TiterCHEK titres less than
1:16 (TITERCHEK® CDV-CPV, Zoetis). Three weeks
after the first immunization (9.3 weeks), 80% of the
dogs already showed a protective CDV SN titer and
this percentage increased to 100% after the second
vaccination (10.7 weeks) (Fig. 1).
With respect to CPV, there was a single animal (20%)
who was protected before vaccination. This animal
showed a TiterCHEK titre equivalent to a 1:80
(TITERCHEK® CDV-CPV, Zoetis). After the first vaccin-
ation at 9.3 weeks, none of the animals were protected
and, after the second vaccination (10.7 weeks), only one
dog (20%; one out of five) developed protection (Fig. 1).
The remaining 80% of the puppies were still unprotected
after the administration of two vaccine doses.
In group B, two animals (B4 and B7) received the first
vaccine 3 weeks before the collection of first blood sample.
On average the first sample was obtained at 9.8 weeks
after birth, the second at 14.2 and the third at 17.8. In this
group, CDV evaluation before vaccination revealed a
protective antibody level in two out of eight dogs. How-
ever, one dog (B4) had been previously vaccinated. After
the first vaccination, all dogs showed CDV protection with
higher values than the protection baseline, which was
maintained after the second vaccination (Fig. 2).
Concerning CPV, one dog showed protective HI titers
before vaccination (B7). However, after the first vaccin-
ation, 50% (4/8) of the animals revealed HI titers higher
than 1:80. After the second vaccination, all animals had
protective titers against this virus (Fig. 2).
In the second immunization point, no significant differ-
ences were found between the seroconversion of groups A
and B for each viral infection (p = 0.81 and 0.20 for CDV
and CPV, respectively). However, in the third immunization
point, there was evidence for higher seroconversion against
CPV in group B (p = 0.015). This result suggested a shorter
time to achieve a protective titer against CPV in this group
when compared to group A (p = 0.015). Similar evidence
was not found for CDV (p-value = 0.41). Both groups ap-
peared then to require the same amount of time to acquire
immunity against this virus.
In Group C, there was only one animal (14.3%) that
was protected against both viruses (Fig. 3). Three dogs
of this group (C2, C5 and C6) had protective titers
against CPV only. The unvaccinated dog n° 7 was un-
protected against both virus as well as dogs C3 and C4.
Overall, 57 and 14% of dogs were protected against CPV
and CDV, respectively. Using data of the vaccinated ani-
mals from this group, SRR was estimated at 0.350 for
CDV. This estimate predicted an average time of
2.86 years to seroreversion. The respective seroconver-
sion rate (SCR) was estimated at zero, a value consistent
with the lack of information to estimate natural expos-
ure to that virus in vaccinated animals. With respect to
Table 1 Ages of dogs in group A and B at the time of sample collection and vaccination. Three blood samples were collected from
each animal at the time of vaccination
GROUP DOG (ID) Age (weeks) 1st sample Age (weeks) 2nd sample Age (weeks) 3rd sample
A A1 6,3 9,3 10,7
A2 6,3 9,3 10,7
A3 6,3 9,3 10,7
A4 6,3 9,3 10,7
A5 6,3 9,3 10,7
B B1 8,9 11,9 15,6
B2 8,7 13,1 20,7
B3 11,7 15,9 19,9
B4 8,9 13,3 16,7
B5 11,1 15,4 21,4
B6 11,1 15,4 21,4
B7 9,6 13,9 18,9
B8 8 12 16
Table 2 Ages of dogs and time elapsed since last vaccination
in group C at the time of sample collection
Dog (ID) Age (years) Time elapsed since last
vaccination (in years)
C1 3,7 3
C2 7 5
C3 6 6
C4 18 8
C5 9 9
C6 16 12
C7 8 Never vaccinated
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CPV, the estimate of SRR was 0.131, which implied an
average of 7.63 years to seroreversion. In this case, the
seroconversion rate is estimated at 0.21, a value associ-
ated with an average of 4.76 years between infections.
Discussion
Vaccination is usually seen as part of a comprehensive
health program for both humans and animals in the
fight against infectious diseases and in the prevention of
future outbreaks [14]. To achieve measurable impacts in
the population, immunization schedules should be opti-
mized according to the specific context of each animal,
including its species, age, habitat, lifestyle, effectiveness
of available vaccines and the underlying disease preva-
lence [10, 13].
In group A, only one dog had a protective titer for CPV
prior to vaccination. This result was consistent with a per-
sistence of maternal antibodies in this animal. After the
second vaccination, only puppy n° 5 was protected for
CPV. Regarding this dog, the vaccine protocol for CDV
and CPV could have ended at 10 weeks of age. In contrast,
almost all dogs were antibody-protected against CDV after
the first vaccination. The variability of the maternal anti-
bodies level may be explained by the amount of colostrum
ingested by the puppies and by the mother’s antibodies
titer [11, 13, 17]. In this case, the titer was the same for all
puppies and therefore the amount of colostrum ingested
by each puppy might be the only variable to consider.
Therefore, the only protected puppy against CPV in the
first assessment probably ingested more colostrum. It is
Fig. 1 Results for CDV and CPV after measurement of the optical densities of the group A samples in the spectrophotometer. The dashed line
corresponds to the optical density of the positive control so that all samples above the dashed line are positive
Fig. 2 Results for CDV and CPV after measurement of the optical densities of the group B samples in the spectrophotometer. The dashed line
corresponds to the optical density of the positive control so that all samples above the dashed line are positive
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likely that the maternal antibodies titer was low for CDV,
not allowing for an effective transfer of antibodies through
colostrum. Despite the fact that only one puppy was pro-
tected against CPV, none of the puppies responded to the
first CPV immunization. These puppies probably had ma-
ternal antibodies against CPV higher than 1:20, which hin-
dered vaccination success [11].
Group B consisted of slightly older dogs, which started
the vaccination protocol after 8 weeks of age. All dogs in
this group developed an immune response to CDV after
the first vaccine administration. Four weeks after the
second administration, which matched with more than
16 weeks of age, all puppies were protected against both
CDV and CPV, thus, ending primary vaccination proto-
col successfully. This suggests a low level of maternal
antibodies at the start of the vaccination protocol, which
were insufficient to neutralize the vaccine antigen at this
age. With respect to CDV, there were no changes be-
tween the results obtained after the first and the second
immunizations, revealing that only one vaccine adminis-
tration could have been enough to protect these puppies
against CDV infection. Regarding CPV, a single puppy
showed a protective titer (higher than 1:80) before be-
ginning the vaccination protocol, revealing a previous ef-
fective immune response, contrary to the other puppy,
which also had been submitted to a previous vaccin-
ation. This variation may be explained by differences in
maternal antibody titers, vaccine type, immune compe-
tence, environmental factors or even by individual bio-
logical differences [21]. Animals from group B would
appear to achieve immunity against CPV faster than the
group A. Similar evidence was not found for CDV.
In group C, only one vaccinated dog was protected
against both viruses (Table 2 and Fig. 3). Three other
vaccinated dogs had a protective humoral immunity
against CPV. Yet, they did not present antibody protec-
tion against CDV. As previously described, CPV is ubi-
quitous and very resistant to adverse conditions and
disinfectants. In contrast, CDV is extremely susceptible
to environmental conditions [4–6]. This results in an in-
creased natural exposure to CPV, leading to more fre-
quent antibody boosts and a quicker development of
immune protection when compared to the less-frequent
CDV. In fact, the occasional exposure to CDV might not
be sufficient to generate strong immune responses that,
ultimately, lead to a protective antibody titer [22, 23].
This interpretation is in line with a zero estimation for
SCR, a common proxy of exposure frequency. However,
this group was very heterogeneous in terms of age, en-
vironmental exposure, immunization schedules and im-
mune system activity [21]. Therefore, the respective
results should be interpreted with caution. However, there
is evidence of a long-term protective immunity induced
by core viral vaccines in adult dogs that had not been
revaccinated for more than 9 years [12, 14, 15]. In fact,
our results suggest that the duration of antibody immunity
against CPV is longer than the one against CDV in these
adult dogs. Unfortunately, there was no information on
the type of vaccines used and immunization schedules in
order to understand this result better. Additional hetero-
geneity in antibody-induced immunity can also be derived
from vaccines produced by different manufacturers, as
demonstrated by a serological survey on 780 dogs vacci-
nated for CDV and CPV [23].
Overall, primary vaccination results for puppies
showed that the antibody response occurred earlier to
CDV vaccination than to CPV. These results suggest
that during primary vaccination the response is individ-
ual and mostly dependent on the initial titer of maternal
antibodies acquired by the neonate [11, 13]. Also, the
Fig. 3 Results for CDV and CPV after measurement of the optical densities of the group C samples in the spectrophotometer. The dashed line
corresponds to the optical density of the positive control so that all samples above the dashed line are positive
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use of multivalent vaccines may induce different im-
mune responses against the immunogenic agents [24].
In some dogs, a single administration may be sufficient
to provide protection, namely against CDV. Therefore,
the use of monovalent vaccines may be advisable in indi-
vidual cases rather than the administration of multiva-
lent ones [24].
The variability found reinforces the importance of
determining the antibody immunity of each animal
[19]. ELISA tests provide an advantageous tool to
confirm protection levels during consultation at a
relatively low cost [19]. These tests should be primar-
ily used to validate vaccine efficacy induced by pri-
mary vaccination, but also to assist the veterinarian in
establishing dog-specific vaccination protocols [18,
20]. These tests may help to identify dogs susceptible
to these infectious diseases as well as to reduce the
frequency of necessary vaccination doses. As sug-
gested by Twark & Dodds (2000), these tests should
be implemented as a routine similarly to what occurs
in the poultry and the pig industry [25]. This would
lead to a better control of core viral diseases, such as
those caused by CDV and CPV infections.
Conclusion
Timely vaccination protocols are essential to prevent in-
fectious diseases, such as those caused by CPV and
CDV. Besides optimization of vaccination schedules,
other factors including dogs’ age, protective antibody
titer or even vaccine type should not be neglected in
assessing the effectiveness of a given vaccine. In this sce-
nario, the present study reinforces the evidence that
antibody response to vaccination is specific to each ani-
mal. This variation supports the necessity of assessing
individual humoral immunity before vaccination. This
evaluation can be easily performed using ELISA assays
during consultation at the veterinary clinic.
Methods
All puppies from 6 to 12 weeks of age submitted to pri-
mary vaccination and adult dogs unvaccinated for at
least 3 years, presented at VTH, were selected to this
study. All dogs included in this study were dewormed
and evaluated by a veterinarian prior to each vaccination
and considered healthy and able to initiate the vaccine
protocol. Animals were distributed by three groups: A –
puppies which started the vaccine protocol at 6 weeks; B
- puppies which started the vaccine protocol at 8 to
12 weeks; C - adult animals, unvaccinated for at least
3 years. Primary vaccination in group A was performed
using the multivalent Nobivac® Puppy DP vaccine (MSD
Animal Health Lda., Paço de Arcos, Portugal); for group
B was used the multivalent Nobivac ® DHPPi vaccine
(MSD Animal Health Lda., Paço de Arcos, Portugal).
Blood samples were collected (0.5 or 1 ml) from the
lateral saphenous vein, prior to the administration of the
first vaccine, and in the subsequent vaccine boosters.
Three blood samples were collected from each animal of
groups A and B at the time of the vaccination consulta-
tions, 3 to 4 weeks apart. The first blood sample was col-
lected before vaccination, allowing the evaluation of
maternal antibodies in vaccine effectiveness. The remaining
samples enabled the determination of the puppy’s immune
response to vaccination. In adult dogs, which were unvac-
cinated for more than 3 years, only one blood sample was
collected to investigate their humoral immunity status for
CPV and CDV. Each sample was then centrifuged
(6000 rpm for 10 min). Plasma was collected and stored in
the freezer at − 20 °C until further use.
Unhealthy dogs, dogs that missed scheduled
immunization appointments, or started vaccination after
12 weeks of age, or whose age was unknown were excluded
from this study.
All procedures involving the manipulation of these
dogs were performed after owner’s written consent and
approval by the Committee for Ethics and Animal Wel-
fare (CEBEA) of the Faculty of Veterinary Medicine –
University of Lisbon, Portugal. All dogs that participated
in this study were client-owned animals which joined
the study during their current vaccination schedule
protocol at VTH. All sampled animals stayed with their
owners after each sample collection.
Antibody evaluation
The antibody response was evaluated using a rapid test
based on the indirect ELISA technique for antibody de-
tection (TiterCHEK® CDV/CPV, Synbiotics Corporation,
San Diego, USA). Results from samples were compared
with the positive control provided, as well as with the
negative control. For CDV, a positive result indicates a
SN titer equal to or greater than 1:16, and a negative re-
sult a SN titer of less than 1:16 [20]. For CPV, a positive
test result indicates a HI titer of 1:80 or higher, and a
negative HI titer of less than 1:80 [20]. According to the
test’s manufacturer, a comparative colorimetric evalu-
ation by direct observation is sufficient to detect the
positivity of a sample; however, this observation was fur-
ther supported with a quantitative measurement of the
absorbance on a spectrophotometer (FLUOstar optima
BMT Labtech) to increase evaluation objectivity. A
standard sample was used and evaluated at different
wavelengths to determine which one should be applied.
Readings were performed at 405 nm.
Statistical analysis
The seroprevalences of groups A and B were compared
with each other at the equivalent immunisation schedule
using a Pearson’s chi-square test for two-way frequency
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table. To compare the induced immunizations against
CDV and CPV, the respective data was transformed into
a frequency vector (f1,f2,f3) where f1 is the frequency of
animals in which transition from seronegative to sero-
positive (e.g., seroconversion) for CDV and CPV oc-
curred in the same time interval, f2 is the frequency of
animals in which seroconversion for CDV occurred earl-
ier than for CPV, f3 is the frequency of animals in which
seroconversion for CPV occurred earlier for CDV. It was
then tested whether both viruses would induce the same
time for seroconversion. This hypothesis was statistically
translated into f2 = f3, or equivalently, f2/(f2 + f3) = 0.5.
A Binomial test using the number of trials equal to f2 +
f3 was used to formally test the hypothesis p = 0.5.
The statistical analysis of the group associated with
adult dogs aimed to estimate the average time until a
vaccinated animal becomes seronegative for each virus.
With that purpose, a simple reversible catalytic model
was fit to the corresponding data. In general, this model
describes the stochastic transitions between seropositiv-
ity and seronegativity as function of age [26]. The re-
spective transition rates are the so-called SCR and SRR
assumed to be constant over time. The former rate is
the frequency by which a seronegative animal becomes
seropositive upon natural exposure to the infection,
while the latter rate is the frequency by which a sero-
positive animal returns to a seronegative state in absence
of recurrent exposure. In this study, it was assumed that
(i) animals were all seropositive after vaccination, (ii) the
time vaccination was the instant zero of the model, (iii)
time since vaccination was the age variable of the model
and (iv) serological outcomes of the individual were de-
rived from independent Bernoulli trials. This model was
then estimated using the maximum likelihood method,
as described elsewhere [26]. Finally, for each virus, the
average time to seroreversion was estimated as the in-
verse of the SRR estimate.
The whole statistical analysis was performed in the
R software version 3.3.2. All statistical tests were car-
ried out at 5% significance level. The sero-aid package
was specifically used to fit the reversible catalytic
model to the data. This package is available from NS
upon request.
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